COMPASS Pathways News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.08.24	Compass Pathways announces second quarter 2024 financial results and business highlights (GlobeNewswire)
26.06.24	Compass Pathways appoints Lori Englebert as Chief Commercial Officer (GlobeNewswire)
08.05.24	Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
08.05.24	Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder (GlobeNewswire)
02.05.24	Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treat (GlobeNewswire)
29.04.24	Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for tre (GlobeNewswire)
28.03.24	Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors (GlobeNewswire)
29.02.24	Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
16.01.24	Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved (GlobeNewswire)
05.01.24	Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement (GlobeNewswire)
19.12.23	Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder (GlobeNewswire)
07.12.23	Compass Pathways appoints Teri Loxam as Chief Financial Officer (GlobeNewswire)
06.12.23	Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry (GlobeNewswire)
15.11.23	Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center (GlobeNewswire)
02.11.23	COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
26.10.23	COMPASS Pathways announces CFO transition (GlobeNewswire)
18.09.23	COMPASS Pathways appoints Daphne Karydas to its Board of Directors (GlobeNewswire)
06.09.23	COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression (GlobeNewswire)
16.08.23	COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors (GlobeNewswire)
03.08.23	COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
25.07.23	First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine (GlobeNewswire)
17.07.23	COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmac (GlobeNewswire)
13.07.23	Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin (GlobeNewswire)
06.07.23	American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies (GlobeNewswire)
31.05.23	COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer (GlobeNewswire)
26.05.23	Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023 (GlobeNewswire)
11.05.23	COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
02.05.23	American Medical Association to Issue First New Code for Psychedelic Therapies (GlobeNewswire)
28.02.23	COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights (GlobeNewswire)
03.11.22	COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
04.08.22	COMPASS Pathways plc announces second quarter 2022 financial results and business highlights (GlobeNewswire)
28.07.22	COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa (GlobeNewswire)
19.07.22	COMPASS Pathways appoints Kabir Nath as Chief Executive Officer (GlobeNewswire)
23.05.22	COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting (GlobeNewswire)
10.05.22	COMPASS Pathways plc announces first quarter 2022 financial results and business highlights (GlobeNewswire)
09.05.22	COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults (GlobeNewswire)
03.05.22	COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022 (GlobeNewswire)
03.05.22	COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression (GlobeNewswire)
20.04.22	COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers (GlobeNewswire)
24.03.22	COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK (GlobeNewswire)
24.02.22	COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights (GlobeNewswire)
17.02.22	COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022 (GlobeNewswire)
19.01.22	Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression (GlobeNewswire)
04.01.22	COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology (GlobeNewswire)
17.12.21	COMPASS Selected for Addition to NASDAQ Biotechnology Index (GlobeNewswire)
16.12.21	COMPASS Pathways announces changes in Executive Team (GlobeNewswire)
13.12.21	COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study (GlobeNewswire)
03.12.21	Michael Falvey joins COMPASS Pathways as Chief Financial Officer (GlobeNewswire)
01.12.21	COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression (GlobeNewswire)
23.11.21	COMPASS Pathways granted fifth US patent for crystalline psilocybin (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu COMPASS Pathways PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten